The Latin America Viral Inactivation Market was worth USD 53.35 million in 2018 and estimated to be growing at a CAGR of 11.2%, to reach USD 90.70 million by 2023. Viral Inactivation is the procedure of killing virus cells or making them inactive. This procedure is performed to prevent contamination of products by viruses and thereby increase the safety. Hence the viruses present in the final product are in inactive form. All these methods are used extensively in blood plasma and food industries to protect the products from viruses.
Among the many methods which are used in inactivation of viruses are irradiation by UV rays, solvent/detergent usage, dry heating, pasteurization, and lowering of pH among others. Pasteurization is a useful only when the viruses are less resistant than the proteins to be protected. Viral Inactivation by solvents and detergents is the most widely used method in the blood plasma industry, effective only when viruses are encapsulated in lipid molecules. The detergents/solvents irritate the lipid layers and kill the viruses since they cannot survive without lipid molecules. UV radiations kill the viruses by dimerising nucleic acids, thus affecting their life cycle and reproduction processes. pH lowering is useful only when the molecules in the final product are more resistant than viruses.
Some of the driving forces of Latin America Viral Inactivation market are attention of research and development industries in life sciences, increasing support of government in biotechnology and pharmaceuticals sectors, growing incidence of chronic diseases, rising support of government in biotechnology and pharmaceuticals sectors and launch of new drugs among others. The constraints that this market is facing are presence of strong consolidation and less number of skilled workers.
The Latin America Viral Inactivation market is segmented on the basis of method, product, application and end-user. Based on method, the market is segmented into solvent/detergent method, pasteurization, UV radiation, microwave heating and high-energy light. The largest market share is held by solvent/detergent method since it requires less investment, easy to use and it achieves high degree of inactivation of viruses. Based on product the market is divided into services, kits and reagents, accessories and viral inactivation systems. With respect to application, the market is fragmented into vaccines and therapeutics, stem cell products, cell culture, gene therapy and blood & blood products. Vaccines and therapeutics has the largest share in this segment. Based on end-users, the market is segmented into academic institutions, research organisations, pharmaceutical companies and others.
The Latin America market for Viral Inactivation is geographically segmented into Brazil, Argentina, Chile and rest of Latin America. The market in this region is still in its nascent stages. Factors such as introduction of new drugs, increasing patients with chronic diseases and growing support of government in biotechnology and pharmaceuticals sectors are presumed to propel the growth of this market in the region.
Some of the major players in the market include Clean Cells, Charles River Laboratories International Inc, Danaher Corporation, Merck KGaA, Parker Hannifin, Red Source Technologies, Sartorius AG, SGS S.A, Texcell Inc, Viral Inactivated Plasma Systems SA, and WuXi Pharma Tech Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Method
5.1.1 Solvent/Detergent Method
5.1.2 Pasteurization
5.1.3 UV Radiation
5.1.4 Microwave Heating
5.1.5 High-Energy Light
5.1.6 Y-o-Y Growth Analysis, By Method
5.1.7 Market Attractiveness Analysis, By Method
5.1.8 Market Share Analysis, By Method
5.2 Product
5.2.1 Kits and Reagents
5.2.2 Services
5.2.3 Accesories
5.2.4 Viral Inactivation Systems
5.2.5 Y-o-Y Growth Analysis, By Product
5.2.6 Market Attractiveness Analysis, By Product
5.2.7 Market Share Analysis, By Product
5.3 Application
5.3.1 Vaccines and Therapeutics
5.3.2 Stem Cell Products
5.3.3 Cell Culture
5.3.4 Gene Therapy
5.3.5 Blood & Blood Products
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
5.4 End User
5.4.1 Pharmaceutical and Biotechnology Companies
5.4.2 Contract Research Organizations
5.4.3 Academic Research Institutes
5.4.4 Other End Users
5.4.5 Y-o-Y Growth Analysis, By End User
5.4.6 Market Attractiveness Analysis, By End User
5.4.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Method
6.1.3.2 By Product
6.1.3.3 By Application
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Method
6.1.4.2 By Product
6.1.4.3 By Application
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Method
6.1.5.2 By Product
6.1.5.3 By Application
6.1.5.4 By End User
6.2 Brazil
6.3 Mexico
6.4 Rest of Latin America
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Clean Cells
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Charles River Laboratories International Inc.
8.3 Danaher Corporation
8.4 Merck KGaA
8.5 Parker Hannifin
8.6 Red Source Technologies
8.7 Sartorius AG
8.8 SGS S.A
8.9 Texcell Inc
8.10 Viral Inactivated Plasma Systems SA
8.11 WuXi Pharma Tech Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
6. Geographical Analysis
